metformin has been researched along with Metrorrhagia in 2 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Metrorrhagia: Abnormal uterine bleeding that is not related to MENSTRUATION, usually in females without regular MENSTRUAL CYCLE. The irregular and unpredictable bleeding usually comes from a dysfunctional ENDOMETRIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to evaluate and compare the effects of spironolactone and spironolactone plus metformin treatments on body mass index (BMI), hirsutism score, hormone levels, and insulin resistance in women with polycystic ovary syndrome (PCOS)." | 9.22 | Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome. ( Acmaz, B; Diri, H; Karaburgu, S; Karaca, Z; Kelestimur, F; Tanriverdi, F; Unluhizarci, K, 2016) |
| "The aim of this study was to evaluate and compare the effects of spironolactone and spironolactone plus metformin treatments on body mass index (BMI), hirsutism score, hormone levels, and insulin resistance in women with polycystic ovary syndrome (PCOS)." | 5.22 | Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome. ( Acmaz, B; Diri, H; Karaburgu, S; Karaca, Z; Kelestimur, F; Tanriverdi, F; Unluhizarci, K, 2016) |
| "Our findings revealed that metformin could induce endometrial atrophy in 21 out of 22 patients (95." | 5.19 | Antiproliferative effect of metformin on the endometrium--a clinical trial. ( Bidadi, S; Foroughi, M; Ghojazadeh, M; Melli, MS; Tabrizi, AD, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tabrizi, AD | 1 |
| Melli, MS | 1 |
| Foroughi, M | 1 |
| Ghojazadeh, M | 1 |
| Bidadi, S | 1 |
| Diri, H | 1 |
| Karaburgu, S | 1 |
| Acmaz, B | 1 |
| Unluhizarci, K | 1 |
| Tanriverdi, F | 1 |
| Karaca, Z | 1 |
| Kelestimur, F | 1 |
2 trials available for metformin and Metrorrhagia
| Article | Year |
|---|---|
Antiproliferative effect of metformin on the endometrium--a clinical trial.
Topics: Adult; Antineoplastic Agents, Hormonal; Atrophy; Carcinoma, Endometrioid; Endometrial Hyperplasia; E | 2014 |
Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome.
Topics: Adolescent; Adult; Blood Glucose; Body Mass Index; Dehydroepiandrosterone Sulfate; Drug Therapy, Com | 2016 |